Jefferies Financial Group Inc. Vertex Pharmaceuticals Inc Transaction History

Jefferies Financial Group Inc.

$13.5 Billion
Q3 2024

A detailed history of Jefferies Financial Group Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Jefferies Financial Group Inc. holds 32,643 shares of VRTX stock, worth $14.7 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

32,643

Previous 60,275 45.84%

Holding current value

$14.7 Million

Previous $28.3 Million 46.27%

% of portfolio

0.11%

Previous 0.32%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $12.7 Million - $14 Million	-27,632 Reduced 45.84%	32,643 $15.2 Million
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $1.36 Million - $1.68 Million	3,453 Added 6.08%	60,275 $28.3 Million
Q1 2024 May 13, 2024	BUY	$407.69 - $446.08 $15.8 Million - $17.3 Million	38,814 Added 215.54%	56,822 $23.8 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $6.07 Million - $7.27 Million	17,707 Added 5882.72%	18,008 $7.33 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $3.6 Million - $3.85 Million	-10,632 Reduced 97.25%	301 $104,000
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $60,054 - $67,214	-191 Reduced 1.72%	10,933 $3.85 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $27,756 - $31,663	-98 Reduced 0.87%	11,124 $3.5 Million
Q4 2022 Sep 21, 2023	SELL	$285.76 - $321.48 $984,443 - $1.11 Million	-3,445 Reduced 31.51%	7,488 $2.16 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $3.21 Million - $3.61 Million	11,222 New	11,222 $3.24 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.

Account

Jefferies Financial Group Inc. Vertex Pharmaceuticals Inc Transaction History